Cholesterol synthesis is the trigger and isoprenoid dependent interleukin-6 mediated inflammation is the common causative factor and therapeutic target for atherosclerotic vascular disease and age-related disorders including osteoporosis and type 2 diabetes

Medical Hypotheses

Volumn 65, Issue 3, 2005, Pages 559-569

  Omoigui, Sota ^a  

^a Division of Inflammation and Pain Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; CHOLESTEROL; CLODRONIC ACID; ETIDRONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IBANDRONIC ACID; INCADRONIC ACID; INTERLEUKIN 6; ISOPRENOID; PAMIDRONIC ACID; RISEDRONIC ACID;

AGE DISTRIBUTION; AGING; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL ACTIVATION; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CORONARY ARTERY DISEASE; DEMENTIA; DRUG MECHANISM; DRUG TARGETING; HUMAN; INFECTION; INFLAMMATION; INJURY; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; REGULATORY MECHANISM; SIDE EFFECT;

AGING; ARTERIOSCLEROSIS; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; OSTEOPOROSIS;

EID: 21844451670     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.03.012     Document Type: Article

References (67)

1. D.G. Hackam, and S.S. Anand Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence JAMA 290 7 2003 932 940
2. P. Libby, P.M. Ridker, and A. Maser Inflammation and atherosclerosis Circulation 105 2002 1135 1143
3. R. Ross Cell biology of atherosclerosis Annu Rev Physiol 57 1995 791 804
4. I. Tabas Free cholesterol-induced cytotoxicity. A possible contributing factor to macrophage foam cell necrosis in advanced atherosclerotic lesions Trends Cardiovasc Med 7 1997 256 263
5. M.M. Kockx Apoptosis in the atherosclerotic plaque: quantitative and qualitative aspects Arterioscler Thromb Vasc Biol 18 1998 1519 1522
6. P.C. Heinrich, J.V. Castell, and T. Andus Interleukin-6 and the acute phase response Biochem J 265 1990 621 636
7. P.M. Ridker, N. Rifai, M.J. Stampfer, and C.H. Hennekens Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men Circulation 101 2000 1767 1772
8. B.C. Berk, W.S. Weintraub, and R.W. Alexander Elevation of C-reactive protein in active coronary artery disease Am J Cardiol 65 1990 168 172
9. P.M. Ridker, M. Cushman, and M.J. Stampfer Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease Circulation 97 1998 425 428
10. M. Cesari, B.W. Penninx, A.B. Newman, S.B. Kritchevsky, B.J. Nicklas, and K. Sutton-Tyrrell Inflammatory markers and onset of cardiovascular events: results from the Health ABC study Circulation 108 19 2003 2317 2322
11. M. Cesari, B.W. Penninx, A.B. Newman, S.B. Kritchevsky, B.J. Nicklas, and K. Sutton-Tyrrell Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study) Am J Cardiol 92 5 2003 522 528
12. King MW. Medical Biochemistry Course Guide, 2004 Cholesterol and Bile Metabolism Indiana University School of Medicine
13. V.S. Dubey Mevalonate-independent pathway of isoprenoids synthesis: A potential target in some human pathogens Curr Sci 83 6 2002
14. Das UN. Statins and the prevention of dementia. CMAJ, 2 October 2, 2001; 165 (7)
15. T. Magee, and C. Marshall New insights into the interaction of Ras with the plasma membrane Cell 98 1999 9 12
16. R. Dechend, D. Müller, J.K. Park, A. Fiebeler, H. Haller, and F.C. Luft Statins and angiotensin II-induced vascular injury Nephrol Dial Transplant 17 2002 349 353
17. S. Akira IL-6-regulated transcription factors Int J Biochem Cell Biol 29 12 1997 1401 1418
18. T.R. Faruqi, D. Gomez, X.R. Bustelo, D. Bar-Sagi, and N.C. Reich Rac1 mediates STAT3 activation by autocrine IL-6 Proc Natl Acad Sci USA 98 16 2001 9014 9019 Epub 2001 Jul 24
19. M. Lubbert, W. Oster, H.P. Knopf, F. McCormick, R. Mertelsmann, and F. Herrmann N-RAS gene activation in acute myeloid leukemia: association with expression of interleukin-6 Leukemia 7 12 1993 1948 1954
20. R. Terkeltaub, J. Solan, M. Barry, D. Santoro, and G.M. Bokoch Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells J Leukocyte Biol 55 6 1994 749 755
21. D.Z. Hillyard, A.G. Jardine, K.J. McDonald, and A.J. Cameron Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes Atherosclerosis 172 2 2004 219 228
22. K. Pahan, F.G. Sheikh, A.M. Namboodiri, and I. Singh Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages J Clin Invest 100 11 1997 2671 2679
23. V.S. Dubey Mevalonate-independent pathway of isoprenoids synthesis: A potential target in some human pathogens Curr Sci 83 6 2002 685 687
24. C.N. Burkhart, and L. Gottwald Assessment of etiologic agents in acne pathogenesis Skinmed 2 4 2003 222 228
25. Vinayak Kapatral, Iain Anderson, Natalia Ivanova, Gary Reznik, Tamara Los, and Athanasios Lykidis Genome sequence and analysis of the oral bacterium Fusobacterium nucleatum strain ATCC 25586 J Bacteriol 184 7 2002 2005 2018
26. K.J. Mattila, M.S. Nieminen, V.V. Valtonen, V.P. Rasi, Y.A. Kesaniemi, and S.L. Syrjala Association between dental health and acute myocardial infarction BMJ 298 6676 1989 779 781
27. H.I. Morrison, L.F. Ellison, and G.W. Taylor Periodontal disease and risk of fatal coronary heart and cerebrovascular diseases J Cardiovasc Risk 6 1 1999 7 11
28. D.H. Meyer, and P.M. Fives-Taylor Oral pathogens: from dental plaque to cardiac disease Curr Opin Microbiol 1 1 1998 88 95
29. R. Assuma, T. Oates, D. Cochran, S. Amar, and D.T. Graves IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis J Immunol 160 1 1998 403 409
30. Sara G. Grossi, Fred B. Skrepcinski, Thomas DeCaro, Don C. Robertson, Alex W. Ho, and Robert G. Dunford Treatment of periodontal disease in diabetics reduces glycated hemoglobin J Periodontol 68 8 1997 713 719
31. Prenylation inhibitors in renal disease A. Khwaja, J. O'Connolly, and B.M. Hendry Lancet 355 2000 741 744
32. U. Ikeda, M. Shimpo, and R.K. Ohki Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells Hypertension 36 2000 325 329
33. J.D. Bergstrom, R.G. Bostedor, P.J. Masarachia, A.A. Reszka, and G. Rodan Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase Arch Biochem Biophys 373 1 2000 231 241
34. M.J. Rogers New insights into the molecular mechanisms of action of bisphosphonates Curr Pharm Des 9 32 2003 2643 2658
35. A. Montagnani, S. Gonnelli, C. Cepollaro, M.S. Campagna, M.B. Franci, and S. Pacini Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate Bone 32 1 2003 15 19
36. H. Nawawi, N.S. Osman, R. Annuar, B.A. Khalid, and K. Yusoff Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin Atherosclerosis 169 2 2003 283 291
37. C. Wuster, and P. Heilmann Bisphosphonate therapy in osteoporosis. Inhibition of trabecular perforation by aminobisphosphonate Fortschr Med 115 29 1997 37 42
38. D. Rendina, L. Postiglione, P. Vuotto, F.G. Numis, G. Di Domenico, and R. Viceconti Clodronate treatment reduces serum levels of interleukin-6 soluble receptor in Paget's disease of bone Clin Exp Rheumatol 20 3 2002 359 364
39. J.M. Olmos, T. De Vega, L. Perera, J.A. Riancho, J.A. Amado, and J. Gonzalez-Macias Etidronate inhibits the production of IL-6 by osteoblast-like cells Meth Find Exp Clin Pharmacol 21 8 1999 519 522
40. N. Giuliani, M. Pedrazzoni, G. Passeri, and G. Girasole Bisphosphonates inhibit IL-6 production by human osteoblast-like cells Scand J Rheumatol 27 1 1998 38 41
41. C. Vitte, H. Fleisch, and H.L. Guenther Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption Endocrinology 137 6 1996 2324 2333
42. N. Abildgaard, J. Rungby, H. Glerup, K. Brixen, M. Kassem, and H. Brincker Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma Eur J Haematol 61 2 1998 128 134
43. A.J. Taylor, S.M. Kent, P.J. Flaherty, L.C. Coyle, T.T. Markwood, and M.N. Vernalis ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness Circulation 106 16 2002 2055 2060
44. Koshiyama Hiroyuki, Nakamura Yoshio, Tanaka Satsuki, and Minamikawa Jun Decrease in carotid intima-media thickness after 1-year therapy with Etidronate for Osteopenia associated with type 2 diabetes J Clin Endocrinol Metab 85 8 2000 2793 2796
45. A.S. Daoud, A.S. Frank, J. Jarmolych, and K.E. Fritz The effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on necrosis of atherosclerotic lesions Atherosclerosis 67 1 1987 41 48
46. J.W. Stephens, S.J. Hurel, J.A. Cooper, J. Acharya, G.J. Miller, and S.E. Humphries A common functional variant in the interleukin-6 gene is associated with increased body mass index in subjects with type 2 diabetes mellitus Mol Genet Metab 82 2 2004 180 186
47. A.D. Pradhan, J.E. Manson, N. Rifai, J.E. Buring, and P.M. Ridker C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 286 3 2001 327 334
48. T. Okamoto, S. Yamagishi, Y. Inagaki, S. Amano, M. Takeuchi, and S. Kikuchi Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro Biochem Biophys Res Commun 297 2 2002 419 424
49. E.B. Jude, P.L. Selby, J. Burgess, P. Lilleystone, E.B. Mawer, and S.R. Page Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial Diabetologia 44 11 2001 2032 2037
50. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, and S.J. Livingstone CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 9435 2004 685 696
51. S. Omoigui The biochemical origin of pain: How a new law and new drugs have led to a medical breakthrough in the treatment of persistent pain 2004 State-of-the-Art Technologies Publishers Hawthorne, CA
52. P.H. Veldman, H.M. Reynen, I.E. Arntz, and R.J. Goris Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients Lancet 342 8878 1993 1012 1016
53. S.C. Manolagas, and R.L. Jilka Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis N Engl J Med 332 5 1995 305 311
54. P. Ravaud, C. Thepot, G.R. Auleley, and B. Amor Imaging of multiple myeloma Ann Med Interne [Paris] 147 1996 370 375
55. G. Teoh, and K.C. Anderson Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma Hematol Oncol Clin North Am 11 1997 27 42
56. G. Teoh, and K.C. Anderson Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma Hematol Oncol Clin North Am 11 1997 27 42
57. S.S. Tabibzadeh, U. Santhanam, P.B. Sehgal, and L.T. May Cytokine-induced production of IFN-β 2/IL-6 by freshly explanted human endometrial stromal cells. Modulation by estradiol-17β J Immunol 142 1989 3134 3139
58. D.M. Kania, N. Binkley, M. Checovich, T. Havighurst, M. Schilling, and W.B. Ershler Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density J Am Geriat Soc 43 1995 236 239
59. R.A. Daynes, B.A. Araneo, W.B. Ershler, C. Maloney, G.Z. Li, and S.Y. Ryu Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative J Immunol 150 1993 5219 5230
60. G. Girasole, R.L. Jilka, F. Passeri, S. Boswell, G. Boder, D.C. Williams, and S.C. Manologas 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens J Clin Invest 89 1992 883 891
61. R.L. Jilka, C. Hangoc, G. Girasole, G. Passeri, D.C. Williams, and J.S. Abrams Increased osteoclast development after estrogen loss: Mediation by interleukin-6 Science 257 1992 88 91
62. K. Nakatsuka Development of bisphosphonates Nippon Rinsho 61 2 2003 219 225
63. G.A. Rodan, and A.A. Reszka Bisphosphonate mechanism of action Curr Mol Med 2 6 2002 571 577
64. D.C. Bauer HMG CoA reductase inhibitors and the skeleton: A comprehensive review Osteoporos Int 14 4 2003 273 282 Epub 2003 May 08
65. H.L. Funkhouser, T. Adera, and R.A. Adler Effect of HMG-CoA reductase inhibitors (statins) on bone mineral density J Clin Densitom 5 2 2002 151 158
66. J.A. Pasco, M.A. Kotowicz, M.J. Henry, K.M. Sanders, and G.C. Nicholson Geelong Osteoporosis Study. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study Arch Intern Med 162 5 2002 537 540
67. A. Staal, J.C. Frith, M.H. French, J. Swartz, T. Gungor, and T.W. Harrity The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity J Bone Miner Res 18 1 2003 88 96